1. Generics Bulletin
  2. >>Business
  3. >>Deals

Three Firms Sign Up With MPP For Long-Acting Cabotegravir

Aurobindo, Cipla And Viatris’s Mylan Agree Deal To Produce HIV PrEP Treatment

 
• By Dave Wallace

Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.

MPP Medicines Patent Pool Logo Hand Syringe
Three firms have signed a deal with the MPP • Source: Shutterstock

Aurobindo, Cipla and Viatris’s Mylan will be able to produce generic versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis to be made available in least developed, low-income, lower-middle-income and sub-Saharan African countries, under licensing deals that the three firms have signed with the Medicines Patent Pool.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business